FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Trading Up 17.1 %

FibroGen stock opened at $0.37 on Friday. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80. The stock has a market cap of $37.24 million, a P/E ratio of -0.30 and a beta of 0.82. The stock has a 50 day moving average of $0.48 and a 200-day moving average of $0.43.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million. As a group, equities analysts predict that FibroGen will post -0.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other FibroGen news, Director James A. Schoeneck bought 250,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $0.35 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now directly owns 323,722 shares of the company’s stock, valued at approximately $113,302.70. The trade was a 339.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.98% of the stock is currently owned by company insiders.

Institutional Trading of FibroGen

A number of institutional investors and hedge funds have recently made changes to their positions in FGEN. Two Sigma Securities LLC acquired a new position in FibroGen during the 4th quarter valued at approximately $27,000. Velan Capital Investment Management LP acquired a new position in shares of FibroGen during the fourth quarter valued at $42,000. XTX Topco Ltd increased its holdings in shares of FibroGen by 423.8% in the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC increased its holdings in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares during the period. Finally, FMR LLC lifted its position in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.